Brad is a seasoned entrepreneur, inventor, and pharmaceutical business executive, boasting over three decades of experience spanning research, development, manufacturing, regulation, financing, and commercialization. Following an extensive career in major pharmaceutical organizations, where he spearheaded the success of blockbuster drugs like LATUDA and LUNESTA, Brad ventured into entrepreneurship. In 2016, he established his first company, Tremeau Pharmaceuticals, securing $110 million in funding. In 2019, Brad founded Lennham Pharmaceuticals and played a pivotal role in guiding the development of d9-caffeine from its inception to achieving GRAS status. Brad holds an honors B.S. in Chemical Engineering from Purdue University, earned an MBA with honors from the Stern School of Business at New York University, and is credited as an inventor on 17 issued US patents.

With experience exceeding 30 years, Jeff has led high-performing teams on a global scale across diverse therapeutic areas within the pharmaceutical industry. Before his role at D9 Designs, he served as the CEO of BioSerenity NA with duties, authorities, and responsibilities consistent with position. Preceding BioSerenity, Jeff was the Executive Vice President and Neurology Head at UCB Pharma, holding a membership in the Executive Committee from 2015 to 2019. In this role, Jeff oversaw the complete value chain of UCB’s neurology portfolio worldwide, managing all activities from post-proof of concept to product lifecycle management, which included drug development, medical affairs, finance, business development, and all commercial activities. Additionally, Jeff assumed the position of Chairman of the Board for both UCB, Inc. in the US and UCB Canada. He holds a Bachelor of Science in Biology from Missouri Southern State University and is a graduate of INSEAD completing the Executive Business Program.

Bruce has over 30 years of clinical medicine practice and academic medicine experience, including over 25 years of research and development experience in the Pharmaceutical Industry. Bruce earned his Doctor of Medicine degree from the Uniformed Services University of the Health Sciences and was a Medical Division Head in the US Navy, also serving with the US Marine Corps as a Flight Surgeon and retired as a Navy Captain. Bruce held various senior executive level scientific positions in the pharmaceutical industry, working in Clinical Development and Medical Affairs leadership roles at Sanofi, Novartis, Bristol-Myers Squibb, and UCB. He held faculty positions at the University of California, San Francisco and Davis, and is currently an Adjunct Professor of Biomedical Science at Georgia State University. As a senior clinical development and regulatory affairs physician, Bruce continues to practice and consult in Internal Medicine, Infectious Diseases, Neurology, Dermatology, and Healthcare Policy.

For the past decade, Joshua Wren has been at the forefront of leading high-performing teams on a national scale. His expertise extends across sales, marketing, branding, web design, and distribution, from startups to established businesses. Prior to his role at d9 Designs, he served as the driving force behind bringing an energy and supplement drink from concept to commercialization. His journey includes extensive experience in Retail and B2B in consumer goods, showcasing a deep understanding of market dynamics. Joshua Wren excels in maintaining and managing diverse and successful sales channels, optimizing each for maximum impact and market reach. Founded in 2021, Joshua owns a marketing and design firm, specialized in assisting businesses, from concept to implementation, ensuring successful commercialization and product launches. A seasoned professional with a proven track record, Joshua Wren transforms ideas into thriving businesses. He holds a B.A. of Business Management from Hope College.

After nearly a decade in the financial services industry with investment management roles at Merrill Lynch and Morgan Stanley, Rusty transitioned to entrepreneurship, co-founding HS Pharmaceuticals, a company specializing in a patented silicate nanotechnology platform for wound care and cancer treatment. As the company's Chief Financial Officer, Rusty provided strategic financial leadership, overseeing budgeting, forecasting, and capital allocation to drive growth and operational efficiency. The innovative silicate technology also led to the creation of ventures in animal science and cosmetics. Recognizing the significant opportunities within the cosmetics industry, Rusty co-founded a second cosmetics company leveraging intellectual property from Clemson University Research Foundation (CURF). As Chief Financial Officer, he directed financial planning, funding strategies, and resource optimization while managing product launches across retail and digital platforms. His strategic leadership was instrumental in guiding the company from concept to commercialization, culminating in an exit following the brand's acquisition. Rusty is a graduate of Furman University, holds a Master's in Accounting from UNC’s Kenan-Flagler Business School, and is a CFA charterholder.